Zogenix, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapies for rare diseases within the United States, striving to profoundly improve the quality of life for affected patients and their families. Their flagship product candidate, Fintepla, a low-dose fenfluramine, is currently undergoing Phase III clinical evaluation for the management of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. Additionally, Fintepla is progressing through Phase II trials to address other less common epileptic syndromes and disorders. Another key pipeline asset is MT1621, an investigational treatment targeting thymidine kinase 2 deficiency, a severe genetic disorder. Zogenix, Inc. has established a collaboration with Tevard Biosciences focused on the research, development, and eventual commercialization of pioneering gene therapies for Dravet Syndrome and other inherited epilepsies. Established in 2006, the company was initially known as SJ2 Therapeutics, Inc. before rebranding as Zogenix, Inc. in August of the same year. Its corporate headquarters are situated in Emeryville, California.


Net sales
Gross margin
Net income